Third Rock Ventures β 2015 Investments
11 investments dated 2015 Β· listed companies and verified rows first Β· show all
BiotechArlington, US
Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)
Board seatRobert TepperΒ· per SEC Form D Β· $7M raise Β· filed Aug 2015
Co-investorsLongitude CapitalSR One Capital ManagementYsios CapitalAtlas VentureLux Capital
NASDAQ-listed (VYGR) biotech in Lexington, MA developing AAV gene therapies and antibodies for neurological diseases.
BiotechLexington, US
Robin Swartz(Executive Officer)Alfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)Steven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)
Board seatMark LevinΒ· per SEC Form D Β· filed Apr 2015
Co-investorsARCH Venture Partners
BiotechSan Mateo, US
Anthony Ford(Executive Officer)Michael Kitt(Executive Officer)Kathleen Sereda Glaub(Executive Officer, Director)
BoardArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatKevin StarrΒ· per SEC Form D Β· $55M raise Β· filed Jul 2015
Co-investorsPappas CapitalDomain Associates
BiotechNewton, US
Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)
BoardAxel Bolte(Director)James Topper(Director)Stephen Kraus(Director)
Board seatRobert TepperΒ· per SEC Form D Β· $53M raise Β· filed Dec 2015
Co-investorsPontifax Venture CapitalFrazier Life Sciences
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)
Board seatRobert TepperΒ· per SEC Form D Β· $55.8M raise Β· filed Dec 2015
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThe Column Group
Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.
Cambridge, US
Board seatNeil ExterCraig MuirKevin StarrΒ· per SEC Form D
Co-investorsage1Samsara BioCapital
BiotechCambridge, US
Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)Richard Murray(Executive Officer, Director)
Board seatRobert KamenCary PfefferRobert TepperΒ· per SEC Form D
Co-investorsNextech Invest
Ann Arbor-founded biopharmaceutical company developing small molecule immunomodulators for autoimmune diseases and cancer.
BiotechAnn Arbor, US
Paul Sekhri(Executive Officer)Gary Glick(Executive Officer, Director)Steve Gillis(Director)Kathleen M. Metters(Executive Officer, Director)
BoardMichael Hayden(Director)
Board seatRobert KamenΒ· per SEC Form D Β· filed Jun 2015
Co-investorsARCH Venture PartnersCanaan Partners
BiotechSouth San Francisco, US
Tassos Anastasios Gianakakos(Executive Officer, Director)
BoardMark Perry(Director)Katherine Bowdish(Director)
Board seatCharles HomcyKevin StarrΒ· per SEC Form D Β· $46M raise Β· filed Apr 2015
Co-investorsForesite CapitalKhosla Ventures
HealthtechBedford, US
Christopher von Jako(Executive Officer, Director)Eric Swanson(Director)Judith M. Huber(Executive Officer)Charles Carignan(Executive Officer, Director)
BoardRussell Hirsch(Director)
Board seatMark LevinΒ· per SEC Form D Β· $40.7M raise Β· filed Nov 2015
Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.
BiotechHealthtechBoston, US
Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inTodd Foley(Director)
Board seatNeil ExterΒ· per SEC Form D Β· $40M raise Β· filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMed
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.